MX381792B - Agente terapéutico para la fibrosis. - Google Patents
Agente terapéutico para la fibrosis.Info
- Publication number
- MX381792B MX381792B MX2017016774A MX2017016774A MX381792B MX 381792 B MX381792 B MX 381792B MX 2017016774 A MX2017016774 A MX 2017016774A MX 2017016774 A MX2017016774 A MX 2017016774A MX 381792 B MX381792 B MX 381792B
- Authority
- MX
- Mexico
- Prior art keywords
- fibrosis
- therapeutic agent
- amino
- therapeutic
- thioxomethyl
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title abstract 4
- 230000004761 fibrosis Effects 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017016774A MX2017016774A (es) | 2018-05-14 |
| MX381792B true MX381792B (es) | 2025-03-13 |
Family
ID=57585165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016774A MX381792B (es) | 2015-06-25 | 2016-06-24 | Agente terapéutico para la fibrosis. |
| MX2020012989A MX2020012989A (es) | 2015-06-25 | 2017-12-19 | Agente terapeutico para la fibrosis. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012989A MX2020012989A (es) | 2015-06-25 | 2017-12-19 | Agente terapeutico para la fibrosis. |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (https=) |
| EP (2) | EP3973962A1 (https=) |
| JP (3) | JP6974167B2 (https=) |
| KR (1) | KR102647942B1 (https=) |
| CN (2) | CN112716952A (https=) |
| AU (1) | AU2016284531B2 (https=) |
| BR (1) | BR112017028137B1 (https=) |
| CA (1) | CA2990791A1 (https=) |
| DK (1) | DK3315131T3 (https=) |
| ES (1) | ES2928684T3 (https=) |
| HU (1) | HUE060732T2 (https=) |
| MA (1) | MA42266A (https=) |
| MX (2) | MX381792B (https=) |
| MY (1) | MY191219A (https=) |
| PH (1) | PH12017502322B1 (https=) |
| PL (1) | PL3315131T3 (https=) |
| PT (1) | PT3315131T (https=) |
| RU (1) | RU2729630C2 (https=) |
| SG (2) | SG11201709260TA (https=) |
| WO (1) | WO2016208744A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| MA42266A (fr) * | 2015-06-25 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agent thérapeutique contre la fibrose |
| HUE068810T2 (hu) | 2017-02-15 | 2025-01-28 | Taiho Pharmaceutical Co Ltd | Gyógyászati készítmény |
| MA50251A (fr) | 2017-09-08 | 2021-06-02 | Taiho Pharmaceutical Co Ltd | Agent antitumoral et potentialisateur d'effet antitumoral |
| US20210369739A1 (en) | 2018-09-18 | 2021-12-02 | Taiho Pharmaceutical Co., Ltd. | Combination therapy of acylthiourea compound and abiraterone |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69939586D1 (de) | 1998-04-28 | 2008-10-30 | Toshikazu Nakamura | Inhibitoren für die gefässneubildung |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| WO2007005668A2 (en) | 2005-06-30 | 2007-01-11 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| CN101360748B (zh) * | 2005-11-30 | 2012-05-30 | 沃泰克斯药物股份有限公司 | c-MET抑制剂及其应用 |
| KR20080080584A (ko) | 2005-11-30 | 2008-09-04 | 버텍스 파마슈티칼스 인코포레이티드 | ｃ-Ｍｅｔ의 억제제 및 이의 용도 |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| ATE523508T1 (de) | 2007-10-25 | 2011-09-15 | Astrazeneca Ab | Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate |
| KR101414931B1 (ko) * | 2008-04-10 | 2014-07-04 | 다이호야쿠힌고교 가부시키가이샤 | 아실티오우레아 화합물 또는 그 염 및 그 용도 |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| EA025304B1 (ru) * | 2010-02-03 | 2016-12-30 | Инсайт Холдингс Корпорейшн | ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ |
| JP5960688B2 (ja) | 2010-05-17 | 2016-08-02 | インコゼン セラピューティクス プライベート リミテッド | プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
| MA42266A (fr) * | 2015-06-25 | 2018-05-02 | Taiho Pharmaceutical Co Ltd | Agent thérapeutique contre la fibrose |
-
2016
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381792B (es) | Agente terapéutico para la fibrosis. | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| HK1249893A1 (zh) | 氘代vx-661 | |
| SG10201902203VA (en) | Eutectic formulations of cyclobenzaprine hydrochloride | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| MX389178B (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| WO2015171558A3 (en) | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE | |
| MY183068A (en) | Pharmaceutical formulation comprising antibody | |
| BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
| BR112017009510A2 (pt) | composições compreendendo ciclosporina | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2017010277A (es) | Cenicriviroc para el tratamiento de la fibrosis. | |
| EP3352750A4 (en) | Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient | |
| MX2019008338A (es) | Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco. | |
| BR112017004552A2 (pt) | composições farmacêuticas | |
| PH12018501758A1 (en) | Oritavancin formulations | |
| PH12021550090A1 (en) | Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof | |
| PH12018501991A1 (en) | Pharmaceutical composition for use in treating fibrosis | |
| MX378376B (es) | Composicion farmaceutica para el tratamiento de la micosis. | |
| MX393608B (es) | Profilactico o agente terapeutico para queratitis fungica. | |
| CO2020006552A2 (es) | Composiciones farmaceuticas que comprenden safinamida | |
| JOP20180128A1 (ar) | صيغة دوائية صلبة قابلة للتشتت في الفم | |
| MX383146B (es) | Composición farmacéutica de disgregación rápida. | |
| TR201721065A2 (tr) | Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar |